Washout Rate of Tc-99m MIBI in Bone and Soft-tissue Sarcomas

Neoadjuvant therapy is employed before the primary treatment of sarcomas. It is not uncommon that it fails due to multi-drug resistance gene causing unnecessary delays in surgery. Tc-99m MIBI, a radiopharmaceutical, is taken-up in these tumours. Being substrate of P-glycoprotein (Pgp), its washout from the malignant tissue may predict the response of sarcoma to neoadjuvant therapy. This book presents the author s experience of in-vivo quantitative estimation of the washout rates of Tc-99m MIBI from nuclear medicine scans of various bone and soft-tissue sarcomas. These rates were then assessed for their ability to predict the effectiveness of neoadjuvant therapy initiated afterwards.

Autorentext

Muhammad Sohaib. Ph.D scholar (Food Technology)National Institute of Food science and Technology, University of Agriculture,Faisalabad,Punjab,Pakistan.Prof.Dr.Faqir Muhammaad Anjum (Tamgha-e-Imtiaz)Director General (NIFSAT),University of Agriculture,Faisalabad,Pakistan.